Saniona AB (SANION) - Total Assets
Based on the latest financial reports, Saniona AB (SANION) holds total assets worth Skr679.74 Million SEK (≈ $73.15 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SANION cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Saniona AB - Total Assets Trend (2012–2025)
This chart illustrates how Saniona AB's total assets have evolved over time, based on quarterly financial data. Explore Saniona AB (SANION) investment intensity to see how much of total assets are deployed in long-term investments.
Saniona AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Saniona AB's total assets of Skr679.74 Million consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr580.82 Million | 85.5% |
| Accounts Receivable | Skr4.36 Million | 0.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr71.39 Million | 10.5% |
| Intangible Assets | Skr4.11 Million | 0.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Saniona AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Saniona AB (SANION) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Saniona AB's current assets represent 88.4% of total assets in 2025, a decrease from 99.4% in 2012.
- Cash Position: Cash and equivalents constituted 85.5% of total assets in 2025, down from 89.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is cash and equivalents at 85.5% of total assets.
Saniona AB Competitors by Total Assets
Key competitors of Saniona AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Saniona AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.48 | 3.08 | 12.32 |
| Quick Ratio | 13.48 | 3.08 | 12.32 |
| Cash Ratio | 13.03 | 2.88 | 0.00 |
| Working Capital | Skr556.36 Million | Skr218.86 Million | Skr514.01 Million |
Saniona AB - Advanced Valuation Insights
This section examines the relationship between Saniona AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.99 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 100.1% |
| Total Assets | Skr679.74 Million |
| Market Capitalization | $188.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Saniona AB's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Saniona AB's assets grew by 100.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Saniona AB (2012–2025)
The table below shows the annual total assets of Saniona AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr679.74 Million ≈ $73.15 Million |
+100.08% |
| 2024-12-31 | Skr339.73 Million ≈ $36.56 Million |
+429.65% |
| 2023-12-31 | Skr64.14 Million ≈ $6.90 Million |
-58.27% |
| 2022-12-31 | Skr153.70 Million ≈ $16.54 Million |
-65.09% |
| 2021-12-31 | Skr440.25 Million ≈ $47.38 Million |
-36.40% |
| 2020-12-31 | Skr692.18 Million ≈ $74.49 Million |
+621.02% |
| 2019-12-31 | Skr96.00 Million ≈ $10.33 Million |
+15.56% |
| 2018-12-31 | Skr83.08 Million ≈ $8.94 Million |
+71.73% |
| 2017-12-31 | Skr48.38 Million ≈ $5.21 Million |
-31.64% |
| 2016-12-31 | Skr70.77 Million ≈ $7.62 Million |
+22.71% |
| 2015-12-31 | Skr57.67 Million ≈ $6.21 Million |
+273.02% |
| 2014-12-31 | Skr15.46 Million ≈ $1.66 Million |
+2.59% |
| 2013-12-31 | Skr15.07 Million ≈ $1.62 Million |
+87.94% |
| 2012-12-31 | Skr8.02 Million ≈ $862.97K |
-- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more